These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 31723184)
21. [Discussion on establishment of quality control system for intensive hospital monitoring on traditional Chinese medicine injections]. Jiang JJ; Xie YM Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2689-91. PubMed ID: 23285909 [TBL] [Abstract][Full Text] [Related]
22. [Construction and implementation of quality control index for clinical safety of Chinese medicine injection]. Jiang JJ; Xie YM Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4766-9. PubMed ID: 27245020 [TBL] [Abstract][Full Text] [Related]
23. [Apply association rules to analysis adverse drug reactions of shuxuening injection based on spontaneous reporting system data]. Yang W; Xie YM; Xiang YY Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3616-20. PubMed ID: 25532406 [TBL] [Abstract][Full Text] [Related]
24. Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial. Stingl JC; Kaumanns KL; Claus K; Lehmann ML; Kastenmüller K; Bleckwenn M; Hartmann G; Steffens M; Wirtz D; Leuchs AK; Benda N; Meier F; Schöffski O; Holdenrieder S; Coch C; Weckbecker K BMC Fam Pract; 2016 Apr; 17():49. PubMed ID: 27112273 [TBL] [Abstract][Full Text] [Related]
25. [Chinese medicine adverse reactions' literature statistical analysis in recent five years]. Xiang F; Zhang X Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(19):2755-8. PubMed ID: 22242443 [TBL] [Abstract][Full Text] [Related]
26. Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: current status and future perspective. Zhang L; Yan J; Liu X; Ye Z; Yang X; Meyboom R; Chan K; Shaw D; Duez P J Ethnopharmacol; 2012 Apr; 140(3):519-25. PubMed ID: 22374080 [TBL] [Abstract][Full Text] [Related]
27. Review of adverse reactions to injections of Chinese materia medica. Bian Z; Shang H; Cheng C; Wu T; Li Y; Zhang B J Evid Based Med; 2010 May; 3(2):88-94. PubMed ID: 21349050 [TBL] [Abstract][Full Text] [Related]
28. Methodological approaches to developing and establishing the body of evidence on post-marketing Chinese medicine safety. Liao X; Robinson N Chin J Integr Med; 2013 Jul; 19(7):494-7. PubMed ID: 23818200 [TBL] [Abstract][Full Text] [Related]
29. [Application of traditional Chinese medicine injections using traditional Chinese medicine theory]. Han W; He E; Cao J Zhongguo Zhong Yao Za Zhi; 2012 Aug; 37(16):2498-500. PubMed ID: 23234156 [TBL] [Abstract][Full Text] [Related]
30. [Current status and development of monitoring on adverse reaction of traditional Chinese medicine in China]. Zhang L; Yang XH; Cao LY; Ji S Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Jul; 25(7):581-4. PubMed ID: 16089130 [TBL] [Abstract][Full Text] [Related]
31. [Interpretation of contemporary positioning of traditional Chinese medicine injections and analysis of key problems]. Gao F; Leng J; Fu CM; Zhang JM; Liao W; Hu HL; He Y; Gan YX; Hao L Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(17):3416-9. PubMed ID: 25522642 [TBL] [Abstract][Full Text] [Related]
32. Reevaluation of the post-marketing safety of Xuebijing injection based on real-world and evidence-based evaluations. Wang C; Shi QP; Ding F; Jiang XD; Tang W; Yu ML; Cheng JQ Biomed Pharmacother; 2019 Jan; 109():1523-1531. PubMed ID: 30551404 [TBL] [Abstract][Full Text] [Related]
33. The safety-influencing factors in use of the tonics of Chinese medicine: a meta-analysis based on the case reports in periodicals. Yu J; Cui M; Li HY; Ye ZG J Tradit Chin Med; 2011 Jun; 31(2):130-5. PubMed ID: 21977814 [TBL] [Abstract][Full Text] [Related]
34. A comprehensive intervention for adverse drug reactions identification and reporting in a Pediatric Emergency Department. Morales Ríos O; Jasso Gutiérrez L; Talavera JO; Téllez-Rojo MM; Olivar López V; Garduño Espinosa J; Muñoz Hernández O Int J Clin Pharm; 2016 Feb; 38(1):80-7. PubMed ID: 26499501 [TBL] [Abstract][Full Text] [Related]
35. Traditional Chinese herbal injection: Current status and future perspectives. Li H; Wang S; Yue Z; Ren X; Xia J Fitoterapia; 2018 Sep; 129():249-256. PubMed ID: 30059719 [TBL] [Abstract][Full Text] [Related]
36. Analysis and study on 47 cases of adverse reactions of Chinese medicine injection. Zhang X; Sang D; Zhang Z; Kong S Afr J Tradit Complement Altern Med; 2014; 11(2):363-4. PubMed ID: 25435623 [TBL] [Abstract][Full Text] [Related]
37. A Retrospective Analysis on 1330 Adverse Event Reports of Qingkailing in China: Further Perception of Its Risks and Rational Use. Wu BL; He WX; Ke M; Shang-Guan XF; He GF; Huang R Curr Med Sci; 2018 Dec; 38(6):1103-1108. PubMed ID: 30536076 [TBL] [Abstract][Full Text] [Related]
38. Present situation and characteristics of Traditional Chinese Medical Informatics (TCMI). Cheng S; Jinyan H; Huamei H; Benlin Y Stud Health Technol Inform; 1998; 52 Pt 2():841-4. PubMed ID: 10384579 [TBL] [Abstract][Full Text] [Related]
39. [Safety evaluation of traditional Chinese medicine injections and study of related key technology]. Cheng F; Liu Z Zhongguo Zhong Yao Za Zhi; 2009 Apr; 34(8):1052-4. PubMed ID: 19639795 [TBL] [Abstract][Full Text] [Related]
40. [Analysis of adverse reactions risk signal of Xinyuan Capsules based on national ADR monitoring spontaneous reporting system]. Wang LX; Xie YM; Cheng WX; Zhong R; Zhuang YN; Wang Q Zhongguo Zhong Yao Za Zhi; 2020 May; 45(10):2310-2315. PubMed ID: 32495586 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]